Answer
Pegvisomant structurally resembles growth hormone and cross-reacts in commercially available growth hormone assays, causing spurious results because therapeutic pegvisomant concentrations are generally 100–1000 times higher than actual growth hormone concentrations in acromegaly, so these tests should not guide treatment monitoring or adjustment.
Sources for this answer
- SOMAVERT 10mg powder and solvent for solution for injectionPfizer Limited · emc · SmPC §4.5 Interaction with other medicinal products · Version 26Document updated
Sources checked